Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Mucin Glycosylating Enzymes in Head and Neck Cancers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01976377
Recruitment Status : Unknown
Verified December 2016 by National Taiwan University Hospital.
Recruitment status was:  Recruiting
First Posted : November 5, 2013
Last Update Posted : December 15, 2016
Sponsor:
Information provided by (Responsible Party):
National Taiwan University Hospital

Brief Summary:
Head and neck squamous cell carcinoma(HNSCC) is the fourth common malignancy in Taiwan. It accounts for 5.8% of all cancers and causes 2,463 deaths per year. Aberrant glycosylation is the hallmark of most human cancers, including HNSCC, and affects many cellular properties. This study is aimed at exploring the role of mucin glycosylating enzymes in HNSCC.

Condition or disease
Glycosyltion Enzymes and Function Abnormalities

Detailed Description:

Glycosylation is the most common post-translational modification of proteins. Aberrant glycosylation is the hallmark of most human cancers and affect many cellular properties, including cell proliferation, apoptosis, differentiation, transformation, migration and immune response.

Though widely explored in various human cancers, the role of mucin glycosylating enzymes in HNSCC has not been elucidated. Our aims is to analyze the expression patterns of mucin glycosylating enzymes in HNSCC tissues. Furthermore, we will correlate the expression levels of mucin glycosylating enzymes with clinical characteristics of HNSCC patients.


Layout table for study information
Study Type : Observational
Estimated Enrollment : 200 participants
Observational Model: Case Control
Time Perspective: Retrospective
Official Title: Expression of Mucin Glycosylating Enzymes in Head and Neck Cancers and Its Correlation With Clinico-pathological Parameters.
Study Start Date : October 2013
Estimated Primary Completion Date : October 2017
Estimated Study Completion Date : October 2017

Resource links provided by the National Library of Medicine


Group/Cohort
Stage I, II, III, IV HNSCC
Stage I, II, III, IV HNSCC reveive treatment in NTUH



Primary Outcome Measures :
  1. Measure the expression of mucin glycosylating in head and neck cancer [ Time Frame: 1~5 years after patient received surgery ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   20 Years to 90 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Head and neck cancer patients receiving operation in National Taiwan University Hospital
Criteria

Inclusion Criteria:

  • Head and neck cancer patients receiving operation in National Taiwan University Hospital

Exclusion Criteria:

  • Recurrence or non-operable patients

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01976377


Contacts
Layout table for location contacts
Contact: Pei-Jen Lou, M.D, Ph.D 886-972651527 pjlou@ntu.edu.tw
Contact: Mei-Chun Lin 886-978261268 b91401051@ntu.edu.tw

Locations
Layout table for location information
Taiwan
National Taiwan University Recruiting
Taipei, Taiwan, 100
Contact: Pei-Jen Lou, MD, PhD    886-972651527    pjlou@ntu.edu.tw   
Contact: Mei-Chun Lin    886-978261268    b91401051@ntu.edu.tw   
Principal Investigator: Pei-Jen Lou, M.D, Ph.D         
Sponsors and Collaborators
National Taiwan University Hospital
Investigators
Layout table for investigator information
Principal Investigator: Pei-Jen Lou, M.D, Ph.D National Taiwan University Hospital

Layout table for additonal information
Responsible Party: National Taiwan University Hospital
ClinicalTrials.gov Identifier: NCT01976377     History of Changes
Other Study ID Numbers: 201307074RIND
First Posted: November 5, 2013    Key Record Dates
Last Update Posted: December 15, 2016
Last Verified: December 2016
Additional relevant MeSH terms:
Layout table for MeSH terms
Head and Neck Neoplasms
Neoplasms by Site
Neoplasms